FibroBiologics, Inc. (SG0.F)

8.45 -0.05 (-0.59%) As of 08:00AM CEST. Market open.

FibroBiologics, Inc.

455 East Medical Center Boulevard
Suite 300
Houston, TX 77598
United States
281 651 5150
https://www.fibrobiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Peter O'Heeron	Founder, Chairman & CEO	884.39k	N/A	1964
Mr. Mark C. Andersen C.F.A., CPA, M.B.A.	Chief Financial Officer	429.65k	N/A	1972
Dr. Hamid Khoja Ph.D.	Chief Scientific Officer	393.6k	N/A	1970
Mr. Ruben A. Garcia	General Counsel	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Corporate Governance

FibroBiologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.